Randomized clinical trials have demonstrated the efficacy of IL-6 blockade with the humanized monoclonal antibody tocilizumab, which is now approved for use in rheumatoid arthritis, giant cell arteritis, and CRS [2]. The gene discussed is IL6; the disease is congenital rubella syndrome.